AZD 5634

Drug Profile

AZD 5634

Alternative Names: AZD5634

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Epithelial sodium channel-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 13 Jun 2017 AstraZeneca initiates a phase I trial for Cystic fibrosis in the US (NCT02950805)
  • 01 Oct 2016 AstraZeneca completes a phase-I clinical trial in Cystic fibrosis (In volunteers) in USA (IV and Inhalation) (NCT02679729)
  • 23 Aug 2016 AstraZeneca plans a phase I trial for Cystic fibrosis in the US (NCT02950805)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top